BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth L. Londoner bought 15,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was bought at an average cost of $7.78 per share, for a total transaction of $116,700.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

NASDAQ:BSGM traded down $0.66 during mid-day trading on Monday, hitting $7.45. The company had a trading volume of 232,483 shares, compared to its average volume of 95,291. BioSig Technologies Inc has a fifty-two week low of $3.50 and a fifty-two week high of $9.97. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.99 and a quick ratio of 10.99.

BioSig Technologies (NASDAQ:BSGM) last released its earnings results on Monday, April 15th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.03). Analysts predict that BioSig Technologies Inc will post -1.17 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of BioSig Technologies in the fourth quarter worth about $48,000. Millennium Management LLC bought a new stake in shares of BioSig Technologies in the fourth quarter worth about $670,000. Deutsche Bank AG bought a new stake in shares of BioSig Technologies in the fourth quarter worth about $58,000. Cornerstone Wealth Group LLC bought a new stake in shares of BioSig Technologies in the first quarter worth about $368,000. Finally, Cambridge Investment Research Advisors Inc. increased its holdings in shares of BioSig Technologies by 49.8% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 90,000 shares of the company’s stock worth $553,000 after acquiring an additional 29,922 shares in the last quarter. 3.91% of the stock is currently owned by hedge funds and other institutional investors.

BSGM has been the topic of several analyst reports. Zacks Investment Research raised BioSig Technologies from a “sell” rating to a “hold” rating in a research note on Thursday. Laidlaw set a $11.00 target price on BioSig Technologies and gave the company a “buy” rating in a research note on Wednesday, February 20th.

ILLEGAL ACTIVITY NOTICE: “Kenneth L. Londoner Purchases 15,000 Shares of BioSig Technologies Inc (BSGM) Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/kenneth-l-londoner-purchases-15000-shares-of-biosig-technologies-inc-bsgm-stock/3017064.html.

BioSig Technologies Company Profile

BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.

Further Reading: What is the quiet period?

Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.